Tandem Diabetes Care, Inc. (TNDM) fair value analysis
Nasdaq · Updated 2026-10-19
TNDM price how computed
Valuation status
Awaiting full valuationTNDM's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once TNDM's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $16.24
- Sector
- Healthcare
- 12-month range
- $12.82–$28.26
- Market cap
- $1.13B
- From 52-week high
- -42.5%
- Shares outstanding
- 69.6M
- Rank in Healthcare by quality score
- #132 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Tandem Diabetes Care, Inc. manufactures and sells insulin pump systems and related products designed to help people with diabetes manage their condition. The company operates globally, serving patients in multiple countries through its diabetes care technology and support services.
TNDM currently ranks #132 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.13B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.04B
- Net margin
- -6.1%
- EPS (TTM)
- $-0.93
- Gross margin
- 56.9%
- Debt / equity
- 5.67
- Revenue growth (3-yr avg)
- 12.4%
- Shares outstanding
- 69.6M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 45 · neutral
- 50-day average
- $19.01
- 200-day average
- $19.13
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-05 (post-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+8.8%)
2026-03 ▲ beat (+31.8%)
2025-12 ▲ beat (+88.9%)
2025-09 ▲ beat (+8.8%)
2025-06 ▼ miss (-20.0%)
2025-03 ▼ miss (-9.8%)
2024-12 ▼ miss (-84.8%)
2024-09 ▲ beat (+12.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 10 hold · 0 sell (24 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $27.8
- Target vs last price
- +71.2%
What our data shows for TNDM
- Shares are trading in the lower third of their 12-month price range of $12.82–$28.26.
- The 14-day relative strength index sits at a neutral 45.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TNDM's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TNDM news
TickrTrends' derived news-sentiment signal for TNDM is currently leaning positive, computed from recent coverage.
- TNDM Maintained by Citigroup -- Price Target Lowered to $20 (gurufocus.com, 2026-09-30)
- Tandem Diabetes (TNDM) Expands Mobi Insulin Delivery System to 12 Countries Outside U.S. (gurufocus.com, 2026-09-28)
- A Look at Tandem Diabetes Care Inc (TNDM) After 3.3% Gain -- GF Value $24.10 vs Price $15.72 (gurufocus.com, 2026-09-26)
What people are saying
Follow the TNDM conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TNDM's 50/200-day trend state shifted from mixed to downtrend this week, indicating a weakening technical position. The Healthcare sector stock remains under valuation review as TickrTrends awaits completion of its full valuation assessment.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TNDM's relative strength index moved from an oversold zone to a neutral zone this week, indicating a shift in its momentum positioning within the Healthcare sector. The stock's valuation assessment remains pending completion of full analysis. This technical adjustment reflects changing price action momentum for the company this week.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TNDM stock undervalued?
TNDM's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is TNDM's TickrTrends verdict?
TNDM is currently marked 'Awaiting full valuation' - a verdict publishes automatically once TNDM's own trailing P/E history validates under our standards.
How does TNDM compare to other Healthcare stocks?
TNDM ranks #132 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TNDM overbought or oversold?
TNDM's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does TNDM report earnings next?
TNDM's next earnings report is scheduled for 2026-11-05 (post-market), per the published earnings calendar.
Does TNDM usually beat earnings estimates?
Over its last 8 reported quarters TNDM beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TNDM?
Of 24 analysts covering TNDM, 14 rate it a buy, 10 a hold and 0 a sell - buy-leaning, with a consensus price target of $27.8 (+71.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.